Search results for: 'radar consisting services'

Computed tomography, X-ray radiography, and magnetic resonance imaging have been invaluable tools in disease diagnosis and treatment efficacy assessments, but the practice of manual viewing and grading medical images to identify abnormalities is time-consuming and can delay diagnosis for critical patients. Intelligent imaging analysis systems that...

Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical r...

As the healthcare industry shifts from a fee-for-service to a fee-for-value model, value-based reimbursement is becoming the standard for accountable care organizations (ACOs), independent physician practices, and non-ACO entities. This transition underscores the essential role of clinical documentation integrity (CDI) specialists, medical coders, ...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

Frost & Sullivan research has identified the core areas in which artificial intelligence (AI)-enabled healtchcare IT solutions are most relevant for hospitals, physicians, and payers. Hospitals that have so far invested in AI-based financial solutions to automate patient access management, reimbursement eligibility matching, and computer-assisted ...

The population health management (PHM) market continues to benefit from provider participation in risk-based reimbursement models, including Medicare Advantage, the Medicare Shared Savings Program, and other value-based care arrangements. As organizations assume greater financial accountability, demand is increasing for platforms that can improve q...

15 Dec 2020  |  Global  |  Frost Radar

Frost Radar™: Advanced Antibodies, 2020

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

Infographics

×

With advances in antibody-based therapies, bispecific antibodies (bsAbs) have gained momentum in the last few years after the regulatory approvals of Amgens blinatumomab (Blincyto®) and Chugais Hemlibra for Hemophilia A. The key advantage of bsAbs lies in their ability to bind two different epitopes or antigens, thereby overcoming the limitations o...

13 Sep 2016  |  North America  |  Market Research

US Next-generation Sequencing Services Market

$1,000 Genome Pricing and Throughput to Drive More and Larger Sequencing Projects

Infographics

×

The next-generation sequencing (NGS) services market includes all sequencing services conducted with next-generation or third-generation platforms that use newer technology than traditional capillary electrophoresis (CE) sequencing. Services include project scoping, NGS sample preparation tasks (i.e., library prep and target enrichment), and NGS-ba...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...